Abstract
The emergence of gene therapy medicinal products (GTMP) has provided novel treatment options for rare diseases. Health technology assessment (HTA) agencies evaluate GTMPs but their reimbursement recommendations can differ, particularly the additional restrictions and real-world evidence (RWE) requirements. Our objective was to review the restrictions and RWE requirements included in HTAs of GTMPs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
